Chronic Myelogenous Leukemia Diagnosis and Treatment

Slides:



Advertisements
Similar presentations
Dr N M Butt Consultant Haematologist
Advertisements

The National CML Society 2012 CML UPDATE “What’s New? What’s Coming?” Luke Akard MD Co-Director Indiana Blood and Marrow Transplantation Program.
Chronic Myeloid Leukemia: Treatment Success and Milestones
DR Discontinuation of second generation tyrosine kinase inhibitors CML and MPDs UK national meeting Newcastle, March 1 st, 2013 Dr Delphine Rea Service.
Final Study Results of the Phase III Dasatinib versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA )1.
Stopping TKI treatment in CML: Who and when
The role of transplant for CML in the imatinib era Dr Wendy Ingram Consultant Haematologist University Hospital of Wales.
Chronic Myeloid Leukemia - Hematology Highlights -
Chronic myeloid leukaemia
Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist Hagop M. Kantarjian, MD Chairman; Professor, Department of Leukemia.
1 Rea D et al. Proc ASH 2014;Abstract 811.
Copyright © 2011 Research To Practice. All rights reserved. Interest in Topics Related to the Treatment of Patients with CML (Percent Responding 9 or 10)
Comparison of Nilotinib and Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd Beyond One Year Larson.
Treatment of CML Transplant or Imatinib? Mark B Juckett MD Section of Hematology/BMT University of Wisconsin.
Ponatinib as Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Cortes JE et al. Proc ASH 2013;Abstract 1483.
Discontinuation of Imatinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Complete Molecular Response: Updated Results of the STIM 1 Discontinuation.
CML in China Qian Jiang, MD Peking University People's Hospital, Peking University Institute of Hematology
SPIRIT3 support includes Biobanking: broadly as for SPIRIT2, but plus genomic DNA (mouth wash via kit) Correlative Science: Biomarkers LSC biology NGS:
What are the risks and benefits of Tyrosine Kinase Inhibitors ? Wendy Osborne Consultant Haematologist Freeman Hospital, Newcastle.
ENESTnd Update: Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and the Impact.
Dose Interruption/Reduction of Tyrosine Kinase Inhibitors in the First 3 Months of Treatment of CML Is Associated with Inferior Early Molecular Responses.
David Marin, Imperial College London Early molecular prediction of response to TKI.
CML TKIs – where are we up to? Steve O’Brien
ENESTnd 24-Month Update: Continued Superiority of Nilotinib versus Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
An Ongoing Phase 3 Study of Bosutinib (SKI-606) versus Imatinib in Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Gambacorti-Passerini.
Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML) Lipton JH.
Dr Nauman Butt – Royal Liverpool University Hospital CML Patient Seminar - 14 th November 2015 What is CML? How do we treat it? Get up to speed…
Dasatinib Compared to Imatinib in Patients with Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase (CML-CP): Twelve- Month Efficacy and Safety.
Initial Findings from the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib,
Switching to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase with Suboptimal Cytogenetic Response on Imatinib: Results from the LASOR.
A Pivotal Phase 2 Trial of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR ‐ ABL Mutation:
Nilotinib versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP):
Dasatinib or Imatinib (IM) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Two-Year Follow-Up from DASISION Kantarjian H et al.
Bosutinib as Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-Up Update Cortes.
Providing Optimal Care for Patients With Chronic Myeloid Leukemia
Future of CML treatments – Are they getting us closer to cure? Andreas Hochhaus Universitätsklinikum Jena, Germany.
Working Groups in Chronic Myelogenous Leukemia: Choice of First-line Therapy This program is supported by an educational grant from.
Michael J. Mauro, MD Associate Professor Knight Cancer Institute, Center for Hematologic Malignancies Oregon Health and Science University Portland, Oregon.
Update on Approved TKIs Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia MD Anderson Cancer Center Houston, Texas.
CML SPIRIT 1, 2 (and 3…) Prof Stephen O’Brien Northern Institute for Cancer Research, Newcastle University Medical School.
Phase III EURO-SKI: Cessation of TKI Therapy Safe, Feasible for Pts Who Achieve Deep Molecular Response New Findings in Hematology: Independent Conference.
CML Shejal Patel DO.
HOW TO TREAT FIRST LINE FAILURE?
Shah N et al. Proc ASH 2010;Abstract 206.
Soverini S et al. Proc ASH 2015;Abstract 346.
Raafat R. Abdel-Malek, MD, FRCR Ass. Prof Clinical Oncology
Early Molecular and Cytogenetic Response Predict for Better Outcomes in Untreated Patients with CML-CP — Comparison of 4 TKI Modalities (Standard- and.
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC Clinical Focus: Options for Treatment-Resistant or Treatment-Intolerant.
Great Debates and Updates in Hematologic Malignancies 2014
Ellen K. Ritchie Clinical Director, Richard T. Silver MPN Center
The Nurse View Key Insights Along the CML Continuum
Great Debates in Hematology
Resistant CML: Understanding the Science to Change Outcomes
Monitoring Milestones in Patients With Chronic Myeloid Leukemia
Great Debates and Updates in Hematologic Malignancies 2014
Imatinib – where are we now. What about generic imatinib
Optimizing Outcomes in the Management of GIST
Clinical Considerations in Evidence-based Management of GIST
Best Practices in Chronic Myeloid Leukemia by Multidisciplinary Teams
Advances in Myeloid Malignancies
Chronic Myeloid Leukemia Challenge
Crossover for pts meeting ELN 2013 failure criteria
Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation by Koichi Miyamura, Kazunori Ohnishi,
Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy.
1Kantarjian HM et al. Lancet Oncol 2011;12:
Branford S et al. Proc ASH 2013;Abstract 254.
Clinical Considerations in Evidence-based Management of GIST
Leber B et al. Proc ASH 2013;Abstract 94.
The Changing Goals of CML Therapy
The Pathway to Progress Against Chronic Myelogenous Leukemia.
Presentation transcript:

Chronic Myelogenous Leukemia Diagnosis and Treatment

Survival in Early CP CML

OS, PFS, and Probability of Remaining in CHR and EFS by ITT Analysis

Outcomes: ENESTnd and DASISION

DASISION: 4-Year Rates of MMR

ENESTnd: Cumulative Incidence of MMR

Progression to AP/BC on Study According to Sokal Risk Score

DASISION: Transformation to AP/BP

ENESTnd: Progression to AP/BC

DASISION: OS and PFS

ENESTnd: 5-Year EFS and PFS

Compliance to Imatinib: ADAGIO Study

Adherence and Molecular Response

Cumulative Incidence of MMR According to BCR-ABL Level at 3 Months

When to Consider Mutational Analysis

Response and PFS With 2G-TKIs in Imatinib-Resistant CP-CML

Newly Approved Agents for CML Patients Resistant or Intolerant to Prior Therapy

Bosutinib Third Line: Best Cumulative Response

PACE: Response to Ponatinib by Previous CP CML Therapy

CCyR Rates After 2G-TKI Failure

ENESTnd: Cardiovascular Events by 5 Years

DASISION: Arterial Occlusive Events

Take-Home Message

IS TKI Therapy Forever? The STIM Trial

Complete Molecular Remission After Discontinuation of Imatinib

Abbreviations

Abbreviations

References

References (cont)

References (cont)

References (cont)

References (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.